A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers

Summary

This is a phase I, open label first in human study to evaluate the imaging performance, safety, biodistribution and pharmacokinetics of \[68Ga\]Ga-DWJ155 in patients ≥ 18 years of age with hormone receptor positive/HER2 negative (HR+/HER2-) and HER2 positive (HER2+) advanced breast cancer (aBC) and advanced Non-Small Cell Lung Cancer (aNSCLC) adenocarcinoma.

Timeline

Start

2026-06-26

Primary completion

2028-12-11

Completion

2028-12-11

Drugs

Indications